Literature DB >> 22257375

The GM-CSF receptor family: mechanism of activation and implications for disease.

Timothy R Hercus1, Sophie E Broughton, Paul G Ekert, Hayley S Ramshaw, Michelle Perugini, Michele Grimbaldeston, Joanna M Woodcock, Daniel Thomas, Stuart Pitson, Timothy Hughes, Richard J D'Andrea, Michael W Parker, Angel F Lopez.   

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pluripotent cytokine produced by many cells in the body, which regulates normal and malignant hemopoiesis as well as innate and adaptive immunity. GM-CSF assembles and activates its heterodimeric receptor complex on the surface of myeloid cells, initiating multiple signaling pathways that control key functions such as cell survival, cell proliferation, and functional activation. Understanding the molecular composition of these pathways, the interaction of the various components as well as the kinetics and dose-dependent mechanics of receptor activation provides valuable insights into the function of GM-CSF as well as the related cytokines, interleukin-3 and interleukin-5. This knowledge provides opportunities for the development of new therapies to block the action of these cytokines in hematological malignancy and chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22257375     DOI: 10.3109/08977194.2011.649919

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  26 in total

Review 1.  Bridge between neuroimmunity and traumatic brain injury.

Authors:  Matthew L Kelso; Howard E Gendelman
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

2.  Endothelial cells expressing low levels of CD143 (ACE) exhibit enhanced sprouting and potency in relieving tissue ischemia.

Authors:  Eduardo A Silva; Chikezie Eseonu; David J Mooney
Journal:  Angiogenesis       Date:  2014-01-11       Impact factor: 9.596

Review 3.  HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication.

Authors:  Jonathan Herskovitz; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2018-03-23       Impact factor: 4.147

4.  The MAPK ERK5, but not ERK1/2, inhibits the progression of monocytic phenotype to the functioning macrophage.

Authors:  Xuening Wang; Stella Pesakhov; Jonathan S Harrison; Michael Kafka; Michael Danilenko; George P Studzinski
Journal:  Exp Cell Res       Date:  2014-10-16       Impact factor: 3.905

5.  Overexpression of transmembrane protein 102 implicates poor prognosis and chemoresistance in epithelial ovarian carcinoma patients.

Authors:  Yi-Jou Tai; Cheng-Miao Ou; Ying-Cheng Chiang; Chi-Fang Chang; Chi-An Chen; Wen-Fang Cheng
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

6.  CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.

Authors:  Mojib Javadi; Terri D Richmond; Kai Huang; Dwayne L Barber
Journal:  J Biol Chem       Date:  2013-05-21       Impact factor: 5.157

7.  Brief report: serpin Spi2A as a novel modulator of hematopoietic progenitor cell formation.

Authors:  Lei Li; Susan M Byrne; Nicole Rainville; Su Su; Edward Jachimowicz; Anne Aucher; Daniel M Davis; Philip G Ashton-Rickardt; Don M Wojchowski
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

Review 8.  A role for G-CSF and GM-CSF in nonmyeloid cancers.

Authors:  Alexander M Aliper; Victoria P Frieden-Korovkina; Anton Buzdin; Sergey A Roumiantsev; Alex Zhavoronkov
Journal:  Cancer Med       Date:  2014-04-02       Impact factor: 4.452

9.  Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis.

Authors:  D E A Greven; E S Cohen; D M Gerlag; J Campbell; J Woods; N Davis; A van Nieuwenhuijze; A Lewis; S Heasmen; M McCourt; D Corkill; A Dodd; J Elvin; G Statache; I P Wicks; I K Anderson; A Nash; M A Sleeman; P P Tak
Journal:  Ann Rheum Dis       Date:  2014-06-16       Impact factor: 19.103

10.  CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.

Authors:  Ugo Testa; Elvira Pelosi; Arthur Frankel
Journal:  Biomark Res       Date:  2014-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.